<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naïve Patients with HIV</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-21</style></pages><abstract><style  face="normal" font="default" size="100%">Results from a 48-week, open-label extension of A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla [SINGLE, NCT01263015], a phase 3, randomized, double-blind trial, have reaffirmed week 48 and week 96 results [Walmsley SL et al. N Engl J Med. 2013] of the superiority of once-daily dolutegravir 50 mg used with abacavir/lamivudine compared with efavirenz/tenofovir/emtricitabine in treatment-naïve patients with HIV-1.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>